Home Print this page Email this page
Users Online: 159
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2016  |  Volume : 5  |  Issue : 3  |  Page : 164-168

Detection of human papillomavirus de-oxy-ribose nucleic acid and its genotypes in cervical cancer patients: A step toward vaccine production

1 Department of Radio-oncology, Sri Aurobindo Medical College and PG Institute, Indore, Madhya Pradesh, India
2 Department of Microbiology, Sri Aurobindo Medical College and PG Institute, Indore, Madhya Pradesh, India
3 White Crescent Diagnostic Center, Indore, Madhya Pradesh, India

Correspondence Address:
Trupti Bajpai
Assistant Professor, Department of Microbiology, Sri Aurobindo Medical College and PG Institute, MR 10 Crossing, Indore - Ujjain Road, Indore, Madhya Pradesh
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/2278-344X.187809

Rights and Permissions

Background: India has a highest global burden of cervical cancer. Infection with a high-risk human papillomavirus (HPV) genotype has been identified as the most important etiologic risk factor for the development of cervical cancer. Aim: The aim of the study was to detect the genotype of high-risk HPV-de-oxy-ribose nucleic acid (DNA) in a patient suspected of cervical cancer and to study the epidemiological factors related to cervical cancer patients. Materials and Methods: The present prospective study was carried out from January 2013 to December 2013 in the molecular medicine laboratory located in our tertiary care super-specialty hospital. Fifty-two female patients who presented in the Gynecology and Oncology Outpatient Department with vaginal bleeding were included in the study. Followed by the detection of HPV genotype using specific markers, restriction fragment length polymorphism was done using different digestion enzymes. Results: Of the 52 cervical samples subjected to polymerase chain reaction for the detection of high-risk HPV-DNA, 44 (84.6%) samples tested positive, and 8 (15.3%) samples lacked the HPV-DNA. The overall distribution of the major HPV types was as follows: HPV16 (50%) was the most prevalent genotype, followed by HPV18 (15.3%). Other genotypes included 1.9% HPV33 and 1.9% HPV62 while infection with the mixed type (HPV16 and HPV18) was seen in 15.3% of patients. Conclusion: As we switch from cytology-based screening to HPV-based screening, genotyping could potentially provide information on individual risk stratification, therapeutic decisions, epidemiological studies, and vaccine development.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded149    
    Comments [Add]    

Recommend this journal